Seven members of the PTC Therapeutics team joined 11 HD-CAB team members for an advisory board on the 3rd November. Sian O’Neill, Senior Director of Patient Engagement EMEA & AP wrote following the meeting to say “Thank you again for the opportunity to participate in the 1st HD-CAB. It was a pleasure to meet such an amazing group of people. The CAB team has pushed the PTC team into overdrive! The real and honest sharing of the reality of HD has generated a lot of questions and dare I say shifted the thought process for our team.”
Novedades
Actualización de Roche/Genentech sobre el estudio GENERATION HD2
Roche/ Genentech anuncian que el estudio de fase II GENERATION HD2 ya está abierto. Esta es una gran noticia para la comunidad internacional, ya que está previsto que se ejecute en 15 países (Argentina, Austria, Australia, Canadá, Dinamarca, Francia, Leer más...